I end the week as I started it: blogging about Vivus and the three-contestant race to make a new prescription diet pill.    Read More

Patients on Vivus' late-stage developmental diet drug, Qnexa, lost an average 37 pounds in 13 months.   Read More

There! I resisted writing a blog headline that attempts some tired play on words with the Arena Pharmaceuticals' clinical trial acronyms BLOSSOM and BLOOM.    Read More

Today is the 16th annual "Newsmakers in Biotech" event put on by Thomson Reuters and BioCentury.    Read More

Some analysts had been telling clients recently that they thought Vivus' diet drug Qnexa could take the lead in the three-contestant race to get the next prescription diet pill on the market. But they didn't think it would take such a commanding lead.    Read More

For years now, but especially in recent months, I've been covering the obesity epidemic. I regularly report on the statistics and the experimental drug data, detached and "objective" as I think any good reporter should be. It just didn't occur to me that the target population might include my sister.   Read More

In less than two weeks, there've been four pretty significant events in biopharma. And, hopefully, after ADA things will begin to settle down a bit for the summer.    Read More